<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285738</url>
  </required_header>
  <id_info>
    <org_study_id>CASE8Y14</org_study_id>
    <nct_id>NCT02285738</nct_id>
  </id_info>
  <brief_title>Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis</brief_title>
  <official_title>Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study examines the safety and feasibility of aspirin with or without
      Simvastatin in solid tumor patients at risk for VTE (Venous Thromboembolism - or blood clots
      - in the arms, lets, lungs, or other part of the body). One-fifth of all thrombotic
      (clotting) events occur in patients that have cancer. Changes in sP-selectin will be used as
      a measure of efficacy. We have chosen sP-selectin as the primary marker because of its role
      in hemostasis, because it is predictive of thrombosis in cancer patients and because of
      promising preliminary data. We expect that sP-selectin levels will be elevated in patients
      before therapy with aspirin and/or statin, but that these levels will fall significantly
      during treatment, rise during the observation phase, and fall during the second study period.
      Patients who take part in the study have been diagnosed with a solid tumor cancer and are
      considered to be intermediate to high risk for VTE. The standard of care is to give
      chemotherapy for solid tumors and treat clots which develop using blood thinners.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

      Primary: To determine efficacy of aspirin with and without simvastatin in solid tumor
      patients at high- or intermediate-risk for VTE, in reducing markers of platelet activation,
      levels of inflammatory and angiogenic cytokines measured using high-throughput approaches,
      and clinical and investigational measures of hemostatic activation.

      Secondary: To determine safety and feasibility of aspirin with or without simvastatin in
      solid tumor patients at high- or intermediate-risk for VTE
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average sP-selectin levels</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>Change in sP-selectin levels as indicator of measure efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of major bleeding complications or clinically significant non-bleeding complications per patient</measure>
    <time_frame>at 17 weeks after beginning treatment</time_frame>
    <description>The safety endpoint will be bleeding complications over 17 weeks (16 weeks of study plus an additional week of observation). This will include major bleeding events and clinically significant non-major bleeding events. A bleeding event will be defined as major if it satisfies one or more of the following: decrease in hemoglobin of 2 g/dL or more, leads to transfusion of two or more units of blood or packed cells, occurs in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leads to death. Clinically significant, non-major bleeding will be defined as bleeding that does not meet the criteria for major bleeding, and has at least one of the following characteristics: multiple-source bleeding; spontaneous hematoma &gt;25 cm2; epistaxis &gt;5 min; macroscopic hematuria not related to instrumentation; spontaneous rectal bleeding; gingival bleeding &gt; 5 min; hemoptysis; hematemesis; or prolonged bleeding (&gt; 5 min) after venipuncture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average Platelet Factor 4</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of platelet activation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average CD40 ligand</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of platelet activation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average serum thromboxane B2</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of platelet activation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average serum VEGF</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of angiogenesis markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average serum angiopoietin-2</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of angiogenesis markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average serum hepatocyte growth factor</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of angiogenesis markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average serum PECAM</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of angiogenesis markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average serum PDGF</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of angiogenesis markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average plasma F1.2</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of hemostatic activation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average plasma TAT complexes</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of hemostatic activation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average plasma D-dimer</measure>
    <time_frame>at 16 weeks of treatment</time_frame>
    <description>measure of efficacy using plasma level of hemostatic activation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of thrombotic events</measure>
    <time_frame>17 weeks after beginning treatment</time_frame>
    <description>the number of thrombotic events measured by the number of events related to venus thrombosis, pulmonary embolism, visceral vein thrombosis as well as arterial thromboembolic events including stroke, myocardial infarction or arterial embolism</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin+Asprin/Simvastatin+Observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin+Observation+Asprin/Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin/Simvastatin+Observation+Asprin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin/Simvastatin+Asprin+Observation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation+Aspirin/Simvastatin+Asprin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation+Aspirin+Asprin/Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81mg/day for 4 weeks</description>
    <arm_group_label>Aspirin+Asprin/Simvastatin+Observation</arm_group_label>
    <arm_group_label>Aspirin+Observation+Asprin/Simvastatin</arm_group_label>
    <arm_group_label>Aspirin/Simvastatin+Observation+Asprin</arm_group_label>
    <arm_group_label>Aspirin/Simvastatin+Asprin+Observation</arm_group_label>
    <arm_group_label>Observation+Aspirin/Simvastatin+Asprin</arm_group_label>
    <arm_group_label>Observation+Aspirin+Asprin/Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Daily dose of Simvastatin for 4 weeks</description>
    <arm_group_label>Aspirin+Asprin/Simvastatin+Observation</arm_group_label>
    <arm_group_label>Aspirin+Observation+Asprin/Simvastatin</arm_group_label>
    <arm_group_label>Aspirin/Simvastatin+Observation+Asprin</arm_group_label>
    <arm_group_label>Aspirin/Simvastatin+Asprin+Observation</arm_group_label>
    <arm_group_label>Observation+Aspirin/Simvastatin+Asprin</arm_group_label>
    <arm_group_label>Observation+Aspirin+Asprin/Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>participants will be observed for thrombotic evens for 4 weeks</description>
    <arm_group_label>Aspirin+Asprin/Simvastatin+Observation</arm_group_label>
    <arm_group_label>Aspirin+Observation+Asprin/Simvastatin</arm_group_label>
    <arm_group_label>Aspirin/Simvastatin+Observation+Asprin</arm_group_label>
    <arm_group_label>Aspirin/Simvastatin+Asprin+Observation</arm_group_label>
    <arm_group_label>Observation+Aspirin/Simvastatin+Asprin</arm_group_label>
    <arm_group_label>Observation+Aspirin+Asprin/Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of malignancy of a solid organ or lymphoma

          -  Planned to initiate a new systemic chemotherapy regimen (including patients starting
             on first chemotherapy or patients previously treated but starting on a new regimen)

          -  VTE Risk Score â‰¥1

          -  Written, informed consent.

        Exclusion Criteria:

          -  Hematologic malignancies including acute and chronic leukemias, myelodysplastic
             syndromes, lymphoma and myeloma

          -  Primary brain tumors

          -  Active bleeding or high risk of bleeding in the opinion of the investigator

          -  Hepatic dysfunction (elevated transaminases or bilirubin &gt; 3 times normal)

          -  Planned stem cell transplant

          -  Life expectancy &lt; 6 months

          -  Acute or chronic renal insufficiency with creatinine clearance &lt; 30 mL/min

          -  Pregnancy

          -  Known allergy to or prior intolerance of aspirin and/or simvastatin.

          -  Ongoing anticoagulant, statin and/or anti-platelet therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alok A Khorana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alok A Khorana, MD</last_name>
    <phone>216-636-2690</phone>
    <email>khorana@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok A Khorana, MD</last_name>
      <phone>216-636-2690</phone>
      <email>khorana@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor, cancer, simvastatin, aspirin, blood clot, VTE, venous thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

